Edwards Lifesciences Co. (NYSE:EW) VP Daveen Chopra Sells 1,250 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The sale was disclosed in a document filed with the SEC, which is available through this link.

Edwards Lifesciences Stock Up 1.6 %

Edwards Lifesciences stock traded up $1.10 during mid-day trading on Tuesday, reaching $69.36. 4,930,151 shares of the company were exchanged, compared to its average volume of 4,083,176. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market cap of $41.80 billion, a P/E ratio of 29.42, a PEG ratio of 2.57 and a beta of 1.11. The business has a fifty day moving average of $80.41 and a 200 day moving average of $85.82. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter last year, the company earned $0.66 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. Research analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. The Goldman Sachs Group decreased their price target on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Oppenheimer cut their target price on shares of Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a report on Thursday, July 25th. Royal Bank of Canada dropped their price objective on shares of Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating for the company in a research note on Thursday, July 25th. Truist Financial cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $110.00 to $82.00 in a research report on Thursday, July 25th. Finally, Canaccord Genuity Group decreased their price objective on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $82.10.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. DSM Capital Partners LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter valued at $28,000. First Community Trust NA acquired a new stake in Edwards Lifesciences during the 2nd quarter worth about $29,000. Riverview Trust Co purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $34,000. Finally, Pingora Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $38,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.